source
- FDA’s new leadership aims to restore reliability, but each application remains judged on its dataThe FDA’s current leadership is working to rebuild the agency’s reputation for reliability, integrity and transparency after a turbulent period under former commissioner Marty Makary. Recent actio…
- Roche bets up to $2.3B on Hanmi’s early-stage muscle-building obesity assetRoche is spending $190 million upfront to license a non-incretin obesity drug from South Korea’s Hanmi Pharm. The deal represents the latest in a string of obesity pacts inked by Roche in recent ye…Endpoints · 16m ago↗ source